Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q14563
UPID:
SEM3A_HUMAN
Alternative names:
Semaphorin III
Alternative UPACC:
Q14563
Background:
Semaphorin-3A, also known as Semaphorin III, plays a crucial role in the development of the olfactory system and the neuronal control of puberty. It induces the collapse and paralysis of neuronal growth cones and acts as a ligand guiding specific growth cones by inhibiting their motility, through binding to the neuropilin-1/plexin-1 complex.
Therapeutic significance:
Semaphorin-3A's involvement in Hypogonadotropic hypogonadism 16 with or without anosmia highlights its potential as a target for therapeutic intervention. Understanding the role of Semaphorin-3A could open doors to potential therapeutic strategies for treating disorders related to olfactory system development and puberty regulation.